AGS supports CMS decision to Maintain Current National Coverage Determination for Monoclonal Antibodies
- AGS supports CMS’ decision to not reopen its NCD on monoclonal antibodies and appreciates CMS’ commitment to review any new evidence that becomes available, such as evidence of clinical benefit, that may lead CMS to reconsider the NCD. http://ow.ly/nExW50N6pS
New York (March 2, 2023) — The American Geriatrics Society (AGS) supports the decision from the Centers for Medicare and Medicaid Services (CMS) to not reconsider its prior national coverage determination (NCD) for Food and Drug Administration (FDA)-approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease (AD). We appreciate CMS’ commitment to expeditiously review any new evidence that comes available that could lead to a reconsideration and change in the NCD, such as evidence that answers the Coverage with Evidence Development (CED) questions or approval by the FDA based upon evidence of clinical benefit.